Entering the third decade of experience with octreotide LAR in neuroendocrine tumors: A review of current knowledge

Gastroenteropancreatic neuroendocrine tumors (NETs) are a relatively rare group of heterogeneous neoplasms. The most significant advance in therapy of NETs has been the advent of the somatostatin analog octreotide, which represents a cornerstone in their management and dramatically changed the thera...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Tumori 2019-04, Vol.105 (2), p.113-120
Hauptverfasser:	Pusceddu, Sara, Prinzi, Natalie, Raimondi, Alessandra, Corti, Francesca, Buzzoni, Roberto, Di Bartolomeo, Maria, Seregni, Ettore, Maccauro, Marco, Coppa, Jorgelina, Milione, Massimo, Mazzaferro, Vincenzo, de Braud, Filippo
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic Agents, Hormonal - therapeutic use Delayed-Action Preparations - therapeutic use Humans Intestinal Neoplasms - drug therapy Neuroendocrine Tumors - drug therapy Octreotide - therapeutic use Pancreatic Neoplasms - drug therapy Stomach Neoplasms - drug therapy
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!